Joel South
All articles

Everything by Joel.

1,263 articles

← Back to profile
Investing

Celanese Price Prediction: Iran Conflict Pushes CE Price Target to $81

Mar 12, 2026
Investing

Atlassian Price Prediction: Down 66%, TEAM Could Hit $185 Next

Mar 12, 2026
Investing

Delta Air Lines Price Prediction: One Wall Street Analyst Sees 50% Upside This Year

Mar 12, 2026
Investing

Occidental Price Prediction: Wall Street Thinks OXY Goes to $69 This Year

Mar 12, 2026
Investing

Micron Price Prediction: One Wall Street Analyst Thinks MU Has 16% More Upside In 2026

Mar 12, 2026
Investing

Alcoa Price Prediction: Middle East Energy Outlook Pushes AA to $68

Mar 12, 2026
Investing

Oracle Price Prediction: One Wall Street Analyst Says ORCL Could Hit $240 This Year

Mar 11, 2026
Investing

Oracle Has A New Price Target of $240

Mar 11, 2026
Investing

BMO and Wells Fargo Raise Targets on Matador (MTDR) and United Natural Foods (UNFI) After Solid Beats

Mar 11, 2026
Investing

Citi Flags Agilent Technologies, Cuts Icon PLC Target, and More

Mar 11, 2026
Investing

Intuitive Surgical Upgraded to Buy by Citi — Plus Key Moves on Stryker and Abbott

Mar 11, 2026
Investing

Oppenheimer Starts Ocugen (OCGN) at Outperform on Gene Therapy Pipeline

Mar 11, 2026
Investing

KeyBanc Flags AeroVironment (AVAV) as Top Iran Conflict Winner

Mar 11, 2026
Investing

Wall Street Still Likes Carnival $CCL But Still Drops Price Target

Mar 11, 2026
Investing

Wall Street Cuts Cipher Mining (CIFR) and TeraWulf (WULF) Price Targets

Mar 11, 2026
Investing

Kohl’s Corporation Faces Fresh Downgrades From Goldman Sachs and JP Morgan

Mar 11, 2026
Investing

AI Disruption Fears Overdone, Says Barclays — Upgrades Arthur J. Gallagher and Willis Towers Watson

Mar 11, 2026
Investing

Warren Buffett’s War-Time Investing Philosophy Is Playing Out in Real Time

Mar 10, 2026
Investing

Wall Street Lifts Targets on Five Below, Ulta Beauty and Nature’s Sunshine Ahead of Key Earnings Reports

Mar 10, 2026
Investing

Gilead Gets a Buy, Amgen a Hold and ORIC a Vote of Confidence: Wall Street’s Latest Biopharma Calls Explained

Mar 10, 2026